ANIKA INITIATES INCERT-S ANTI-ADHESION THERAPY CLINICAL
TRIAL.
Anika Therapeutics, Inc. (Nasdaq:ANIK), Woburn, Mass. has commenced
a human pilot clinical trial testing the safety and effectiveness of
INCERT-S for the prevention of internal adhesions or . . .
FDA GRANTS TENTATIVE APPROVAL OF SICOR'S FLUMAZENIL
INJECTION.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), Jerusalem,
Isarael, has announced that the U.S. Food and Drug Administration has
granted tentative approval for an ANDA for Flumazenil Injection, . . .
EVOTEC OAI/PANACOS TO DEVELOP ANTI-HIV THERAPIES.
Evotec OAI AG (Deutsche Borse: EVT, TecDAX 30), a partner for
integrated high-value-added drug discovery and development solutions to
the pharmaceutical and biotechnology industries, and . . .
AERAS/CRUCELL TO DEVELOP TB VACCINE.
Crucell N.V., Leiden, The Netherlands, and the Aeras Global TB
Vaccine Foundation of Bethesda, Maryland, have announced a new
collaboration on the pre-clinical and clinical development of . . .
OREXO PATENT FOR RAPID DELIVERY ISSUED IN EU.
Orexo Pharmaceuticals has announced that a European Patent has been
granted for one of their technology platforms, the sublingual tablet
technology. Several of the company's product projects are . . .
AVIDEX APPOINTS ULTRAFINE TO DEVELOP/MANUFACTURE RHUDEX.
Avidex Ltd., Oxford, UK, has appointed Ultrafine (UFC Ltd.,
Manchester, UK), to provide process development, scale-up and GMP
manufacturing for Avidex' lead compound, the CD80 inhibitor,
RhuDex.
. . .
ROCHE SELECTS TWO GENMAB ANTIBODIES AS CLINICAL
CANDIDATES.
Genmab A/S has announced that Roche has selected two Genmab
antibodies as candidates for clinical development. The antibodies,
developed under a collaboration between Roche and Genmab which began . . .
GBC BIOTECH PRESENTS NEW DATA ON EFFICACY OF SATRAPLATIN.
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30) has
announced the presentation of new in vitro data on the efficacy of
satraplatin in tumor cells resistant to both TAXOTERE (docetaxel) . . .
ABBOTT/EUROPROTEOME TO DEVELOP BREAST CANCER DIAGNOSTIC
TESTS.
Abbott Laboratories (NYSE: ABT), Abbott Park, Ill. and Europroteome
AG, of Berlin-Hennigsdorf, Germany, have entered into a research
collaboration for the discovery and development of in vitro . . .
EPT'S IMPLANT TRIAL EXCEEDS EXPECTATION.
EpiTan Limited [ASX: EPT], Melbourne, Australia, has announced
better than expected efficacy in its implant dose escalation trial which
commenced in November 2003. The first six volunteers, who . . .
DXS AND SANGTEC SIGN SCORPIONS TECHNOLOGY LICENSE PACT.
DxS Ltd, a genotyping services and personalized medicine company,
and Sangtec Molecular Diagnostics AB, a company specialized in
developing and marketing standardized clinical molecular . . .
NEXMED LICENSES FEMPROX TO CJ CORP. FOR SOUTH KOREA.
NexMed, Inc. (Nasdaq: NEXM), Robbinsville, N.J., has announced that
CJ Corporation, one of the top five pharmaceuticals companies in South
Korea, has licensed Femprox for Korea. Femprox is . . .
EUROPEAN COMMISSION APPROVES ZEVALIN RADIOIMMUNOTHERAPY.
Biogen Idec (NASDAQ: BIIB) has announced that the European
Commission has granted marketing approval for ZEVALIN(r) (Ibritumomab
tiuxetan) radioimmunotherapy. ZEVALIN is approved in Europe for . . .
OCTOPLUS/LUMC BEGIN TRIALS FOR MIDDLE EAR INFECTION DRUG.
An innovative drug against chronic middle ear infection has gone
into patient trials in Leiden, The Netherlands. Drug delivery and
development company OctoPlus and the Leiden University Medical . . .
ENZON/INEX SIGN COMMERCIALIZATION PACT FOR ONCOLOGY DRUG ONCO
TCS.
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) and Inex Pharmaceuticals
Corporation (TSX: IEX) have formed a strategic partnership to develop
and commercialize INEX's proprietary oncology product Onco . . .
CAMBRIDGE ANTIBODY TECHNOLOGY/AMGEN RESTRUCTURE
AGREEMENT.
Cambridge Antibody Technology Group plc (CAT), Cambridge, England,
has announced the restructuring of an existing antibody development and
marketing collaboration agreement with Immunex . . .
MORPHOSYS/PFIZER TO DEVLOP THERAPEUTIC ANTIBODIES.
MorphoSys AG, Germany, (Frankfurt Stock Exchange: MOR; Prime
Standard Segment) has entered into a collaboration with Pfizer Inc. for
the development of therapeutic antibodies. MorphoSys will use . . .
DOW AGROSCIENCES/UNIV. OF GUELPH DEVELOPING CATTLE
VACCINE.
Dow AgroSciences Canada Inc. has signed a research and licensing
agreement with the University of Guelph, which is conducting research on
a promising new vaccine to prevent a major flu-like disease . . .
SHIRE LICENSES AGRYLIN TO KIRIN PHARMACEUTICAL IN JAPAN.
Shire Pharmaceuticals Group plc (Nasdaq: SHPGY; LSE: SHP; TSX:
SHQ), Basingstoke, England, has been signed an agreement with a leading
haematology specialty company, the Pharmaceutical Division of . . .
FDA APPROVES TRINITY'S UNI-GOLD RECOMBIGEN HIV TEST.
Trinity Biotech plc (NASDAQ: TRIB), Dublin, Ireland, has received
approval from the U.S. Food and Drug Administration (FDA) to market its
Uni-Gold Recombigentm HIV test in the United States.
The . . .
|
|